Additionally, the expression of PD-L1 in both tumor and immune cells has been correlated to ICI clinical responses, making accurate PD-L1 characterization a valuable companion diagnostic for PD-1/PD-L1 inhibitors. Here, CD274 is linked to neoplasm.